glp-1 drugs and autoimmune disease The Thyroid Twist: How Agonists Are Influencing Thyroid Care GLP1 microdosing for autoimmune conditions?

The local increase in GIP stimulates vagal afferent transmission followed by activation of vagal efferents and enteric neurons that release acetylcholine and/or GRP to stimulate GLP-1 release from the distal gut

For subcutaneous semaglutide, we recommend starting 0.5 mg once weekly for 4 weeks before advancing to 1 mg once weekly, depending on tolerability and clinical necessity

Rondanelli M, Perna S, Riva A, Petrangolini G, Di Paolo E, Gasparri C

Glaucoma represents the leading global cause of irreversible blindness, with ongoing demographic shifts toward an aging population, its prevalence is projected to increase substantially in the coming decades [12]

10.1007/s11695-009-0014-5 13 CalaraF.TaylorK.HanJ.ZabalaE.CarrE

Pendulum's formula was built around this systems understanding of gut health supporting the complete microbiome environment rather than simply adding bacterial colony counts that address digestion in isolation